Short answer
Nuvectis Pharma, Inc. (NVCT) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results and corporate update announced for quarter ended June 30, 2026.
Nuvectis Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results and corporate update announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operating details
- Disclosure furnished under Item 2.02, limiting Section 18 liability and incorporation by reference
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $7.0M versus $6.3M; R&D rose to $4.7M from $3.6M as development activity accelerated
- July follow-on offering raised $115M gross, extending stated cash runway into 1H 2029 but increasing share dilution risk
- Ciprocopan gained China approval for previously untreated PNH patients, validating NXP100 and establishing the company’s lead late-stage asset
- U.S. pre-IND meeting and IND submission for NXP100 expected in 4Q 2026, creating near-term regulatory catalysts
- NXP200 Phase 1b ongoing while NXP900 development shifts toward combination studies, concentrating resources on higher-potential programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvectis Pharma, Inc. 8-K filings
Get the next NVCT 8-K as it lands
Follow NVCT for push alerts, or ask the research agent what this filing means.